MEDINCELL - BUY | EUR9.7 vs. EUR10.3 (+30%) Interim read-out for mdc-IRM’s phase III delayed into H2 2020 Unsurprising first-half numbers Status update for mdc-IRM: a difficult-to-interpret new delay What does it mean? We need to adjust our FV
MEDINCELL - BUY | EUR10.3 vs. EUR10 (+48%) Mdc-WWM (contraception) moves forward with the support of the BMGF MedinCell to receive up to USD19m in grants Another validation of the technology MedinCell is holding rights in developed markets FV adjustment to the cash received
MEDINCELL - CORPORATE | EUR10(+55%) Creates new pure financial opportunity in animal healthcare Animal health was a target for BEPO MedinCell partners with a US specialist in A.H. An attractive financial opportunity Animal Health will be a new free upside to our central case
MEDINCELL - BUY | EUR10(+43%) An interesting read-across from recent deal signed by Durect An inspiring deal between Gilead and Durect Confirmation of value in LA formulations HIV: a new area for LA formulations? Strong rationale for MedinCell to play in HIV
MEDINCELL - BUY | EUR10 Several catalysts and opportunities to create value to come over the next 12 months The situation at the end of March is in line with expectations The reminder of the calendar year has two key catalysts New projects, new partnerships in perspective An unchanged FV
MedinCell has developed a proprietary technology called BEPO® which makes it possible to develop the formulation of molecules as long-acting injectables. This presents clear advantages for compounds in diseases where convenience and adherence to treatment matter the most. Therefore, it combines an attractive market opportunity with a fairly low risk of development.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.